Don't miss
-
Proffered paper session - Rare Cancers
20 March 2023, h. 10:50-12:10 -
Proffered paper session - Sarcoma
21 March 2023, h. 10:50-12:10 -
Mini oral session
22 March 2023, h. 9:00-10:00
EDITORIAL
The evolving landscape of rare tumour molecular characterisation
Continued collaboration to identify new molecular targets and treatments can build on existing success
ESMO SARCOMA AND RARE CANCERS CONGRESS 2023
Surgery remains the key to progression-free survival in ovarian sex cord-stromal tumours
Two studies presented by the French network TMRG-GINECO provide new insights into the treatment and quality of life of women with this rare cancer
Access to high-quality care for sarcomas is still unequal worldwide
Delays and poor patient journey are reported in resource-constrained countries, while awareness campaigns and healthcare service reorganisation have improved rare cancer management in more developed areas
Molecular profiling of neuroendocrine neoplasms reveals markers with prognostic and therapeutic relevance
A Spanish study describes the genomic characterisation of neuroendocrine neoplasms as the first step towards more personalised management
Sinonasal cancer: whole-exome sequencing reveals potential therapeutic targets
Results from a study suggest that some existing inhibitors may benefit all subtypes of these rare malignancies, which currently lack effective treatments
COLUMNS
Early drug development: paving the way to patient-centred design
Adding precision to dose-finding in early-phase clinical trials has become critical in the immunotherapy era, and moving away from paradigms of the past has become mandatory
Gathering preclinical pace: cellular immunotherapy against solid tumours
Two recently published studies provide preclinical insights into ‘training’ CAR T cells that may potentially lead to more effective and less toxic immunotherapy approaches
Topics
Improving patient involvement in rare cancers
Andres Cervantes
Patients as partners to address unmet needs in sarcoma
Ornella Gonzato